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DESCRIPTION of CASE
A
50-year-old man was referred to the Cognitive 
Function Clinic with a 12- to 18-month history of 
deterioration in his memory. The symptoms reported 
by the patient and his wife included forgetting what he was 
supposed to be doing, occasional disorientation in place, 
misplacing objects, and word-finding difficulties, all of which 
had affected his occupational function as a high school 
teacher. His past medical history was unremarkable. In the 
family history, his mother was said to have had Alzheimer 
disease (AD) in her fifties and died in her sixties, but no 
further details were available to confirm or refute this. The 
patient’s neurological examination was normal.
Initial Investigations 
On the Mini-Mental State Examination (MMSE; see Box 1 
for brief descriptions of cognitive tests), the patient scored 
26/30 with evidence of impaired delayed recall. Initial 
neuropsychological assessment showed no evidence of 
generalised intellectual loss, since the full scale IQ measured 
with the Wechsler Adult Intelligence Scale–Revised (WAIS-R) 
was 109, comparable to the predicted premorbid full scale 
IQ of 100 measured with the National Adult Reading Test 
(NART). He was within normal limits on tests of memory. In 
tests of executive function using verbal fluency and the Stroop 
test, the patient was within normal limits and showed no 
perseverative errors or rule breaks. Structural brain imaging 
with computed tomography (he could not tolerate magnetic 
resonance brain imaging) was within normal limits. Despite 
these apparently reassuring results, follow-up for longitudinal 
assessment was recommended, in part because the symptoms 
affected occupational function and in part because of the 
family history.
Over the next two years, the patient and his family noted 
further decline in memory function. New symptoms included 
repetitive questioning and difficulty remembering tasks to be 
done. He had to give up work, and his wife took over running 
the household finances. At reassessment, MMSE score was 
stable, but on the Addenbrooke’s Cognitive Examination 
he scored 81/100 with evidence of impaired delayed recall. 
Repeat neuropsychological assessment showed a decline in 
intellectual performance (37 point fall in WAIS-R Verbal 
IQ) and deterioration in all measures of auditory and visual 
memory for immediate and delayed recall, but with normal 
working memory. There was also deterioration in word-
finding and naming abilities (Graded Naming Test) and 
in tests of executive function (verbal fluency, Stroop test). 
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Box 1: Description of Cognitive Tests
Mini-Mental State Examination (MMSE)
A brief (5–10 minutes) mental status questionnaire assessing 
attention, orientation, memory, language, and visuospatial 
copying.
Wechsler Adult Intelligence Scale–Revised (WAIS-R)
Widely used test battery of general cognitive abilities, deriving 
a full scale IQ from six subtests that comprise Verbal IQ and five 
subtests that comprise Performance IQ. Administration time 
1–2 hours; may require more than one consultation if patients 
become fatigued.
National Adult Reading Test (NART)
A reading test of 50 irregularly spelled words. Since this function 
is relatively preserved in some forms of dementia, the NART 
may be used to estimate premorbid cognitive function, since 
longitudinal assessments of IQ are almost never available in 
initial clinical evaluation.
Verbal Fluency Tests
Generation of words beginning with a particular letter (Letter or 
Phonemic fluency), or exemplars of a particular category (Category 
or Semantic fluency) in one minute; tests of executive function.
Stroop Test (Colour–Word Interference Test)
Reading names of colours printed in inks of different colour; 
reading the names is much easier than reading the conflicting 
colours (inhibition task); test of executive function.
Addenbrooke’s Cognitive Examination
A development of the MMSE addressing some of its 
shortcomings, with more detailed tests of memory, language, 
visuospatial, and executive function, and hence longer to 
administer (15–20 minutes).
Graded Naming Test
Patient must name 30 black-and-white line drawings, sequenced 
in order of difficulty; a test screening for naming deficits.PLoS Medicine  |  www.plosmedicine.org 0036 January 2009  |  Volume 6  |  Issue 1  |  e1000019
Computed tomography brain imaging was now reported to 
show atrophy of the temporal lobes.
What Is the Differential Diagnosis?
After two years of follow-up and investigation, this man 
fulfilled clinical diagnostic criteria for the diagnosis of 
dementia as enshrined in the Diagnostic and Statistical Manual 
of Mental Disorders [1], namely “the development of multiple 
cognitive deficits that include memory impairment…
sufficiently severe to cause impairment in occupational or 
social functioning”. 
The differential diagnosis of the cause of dementia is 
potentially broad (Box 2), although the majority of cases 
result from AD, with or without concurrent cerebrovascular 
disease. In dementia of young onset, arbitrarily defined 
as clinical onset before 65 years of age, the differential 
diagnosis is more varied [2,3]. Syndromes of frontotemporal 
lobar degeneration (FTLD) are more common, and indeed 
may be equal in frequency to AD in this age group [4]. 
In FTLD there is focal brain degeneration, which may 
show a predilection for the frontal lobes presenting with a 
behavioural phenotype, the behavioural or frontal variant 
of frontotemporal dementia, or for the temporal lobes 
presenting with a linguistic phenotype, either progressive 
non-fluent aphasia (PNFA) or semantic dementia. Overlap 
between FTLD and motor neurone disease, and movement 
disorders such as corticobasal degeneration and progressive 
supranuclear palsy, is also recognised [5]. Memory 
complaints are not uncommon in patients with FTLD, and 
many patients meet current clinical diagnostic criteria for 
AD [6]. However, memory deficits may be a relatively minor 
feature in FTLD, and standard screening tests such as the 
MMSE are insensitive to the diagnosis. Clinical suspicion 
should be raised when the extent of functional impairment 
appears inconsistent with the degree of cognitive deficits, 
requiring evaluation for cognitive deficits other than 
memory. Psychiatric illness, particularly depression, also 
enters the differential diagnosis.
Other conditions that need to be considered include 
vascular dementias, alcohol-related dementia, and traumatic 
brain injury. There are many neurological disorders that 
may also be attended with cognitive impairment, sometimes 
of sufficient severity to mandate a diagnosis of dementia. 
These so-called secondary dementias often present with 
other neurological signs in addition to dementia, such as 
parkinsonism, myoclonus, seizures, chorea, ataxia, and 
sensory signs. 
Dementias inherited as monogenic Mendelian disorders 
(Box 3) are also more common with young-onset disease, 
although still rare. Examples include AD associated with 
mutations in the presenilin 1, presenilin 2, or amyloid 
precursor protein genes, FTLD associated with mutations in 
the tau or progranulin genes, and Huntington disease [7].
Initial Formulation and Treatment
A provisional diagnosis of probable young-onset familial AD 
was made, based on the NINCDS-ADRDA (National Institute 
of Neurological and Communicative Diseases and Stroke–
Alzheimer’s Disease and Related Disorders Association) 
clinical diagnostic criteria of AD [8], and the family history 
of one other affected individual. The stringent definition of 
autosomal dominant disease transmission requires a family 
history with at least three affected individuals in at least two 
generations [9], which was not known to be the case in this 
family.
The patient was treated with cholinesterase inhibitors, 
licensed for the treatment of mild-to-moderate AD in 
this jurisdiction, but these produced no subjective or 
objective benefit despite switching between the different 
cholinesterase inhibitors [10]. Two years after diagnosis 
Box 2: Differential Diagnosis of Dementia
sÈ .EURODEGENERATIVEÈDISORDERS
º AD +/− cerebrovascular disease 
º Parkinson disease dementia/dementia with Lewy bodies
º FTLDs:
      ▪ Behavioural variant frontotemporal dementia 
    ▪  PNFA
    ▪  Semantic  dementia 
º Prion diseases
sÈ 6ASCULARÈDEMENTIAS
sÈ !LCOHOL
RELATEDÈDEMENTIA7ERNICKE
+ORSAKOFFÈSYNDROME
sÈ 3TRUCTURALÈBRAINÈDISEASE
º Severe traumatic brain injury
º Tumours +/− radiotherapy
sÈ )NFLAMMATORYÈBRAINÈDISORDERSÈEGÈMULTIPLEÈSCLEROSIS
sÈ 3O
CALLEDÈhREVERSIBLEÈCAUSESvÈVERYÈRARE	
º Neurosyphilis
º Hypothyroidism
º Vitamin B12 deficiency
Box 3: Differential Diagnosis of Dementia 
Syndromes Inherited as Monogenic Mendelian 
Disorders
sÈ )NHERITEDÈDEMENTIAS
º Huntington disease
º Familial AD
º Familial FTLD
º Inherited prion disease
sÈ )NHERITEDÈVASCULOPATHIES
º Cerebral autosomal dominant arteriopathy with subcortical 
      infarcts and leukoencephalopathy
º Familial British dementia, familial Danish dementia
sÈ )NHERITEDÈMOVEMENTÈDISORDERSÈATAXIASÈMETABOLICÈDISORDERSÈ
that may be complicated by cognitive decline and dementia:
º Wilson disease
º Dentatorubropallidoluysian atrophy
º Presenile dementia with bone cysts
º Some spinocerebellar ataxias
º Some hereditary spastic paraplegias
º Neurodegeneration with brain iron accumulationPLoS Medicine  |  www.plosmedicine.org 0037 January 2009  |  Volume 6  |  Issue 1  |  e1000019
the patient completed independent screening for a 
pharmaceutical company–sponsored trial of a potential 
new AD medication by meeting all specified inclusion and 
exclusion criteria.
Clinical Progress
At the age of 56, about seven years after the first onset of 
symptoms and four years after the diagnosis of probable 
AD, the patient developed new neurological symptoms and 
signs. He complained of a stiff neck, falls both forward and 
backward, occasional choking, and difficulty articulating 
(as opposed to finding) his words. Increasing apathy was 
also noted retrospectively, a possible and easily overlooked 
cause of his initial occupational difficulties. Neurological 
examination was now abnormal, showing slowed horizontal 
saccadic eye movements with reduced amplitude vertical 
saccades, dysarthria, a broad-based gait with postural 
instability, and a positive applause sign. 
Further Formulation and Investigations
Had it not been for the presence of dementia of Alzheimer 
type, these new non-cognitive neurological symptoms 
and signs were judged to be consistent with a diagnosis of 
probable progressive supranuclear palsy (PSP), based on 
NINDS-SPSP (National Institute of Neurological Disorders 
and Stroke–Society for Progressive Supranuclear Palsy) 
diagnostic criteria [11]. The chance concurrence of two 
diagnoses, probable AD and PSP, was thought unlikely 
and hence, seeking a more parsimonious explanation, 
neurogenetic testing of the tau gene was undertaken. 
This testing showed the patient to be heterozygous for the 
splice site mutation C915 +16 C > T at the exon 10/intron 
10 boundary (denoted 10 +16), indicating a diagnosis of 
frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17) (Online Mendelian Inheritance 
in Man, catalogue entry +157140) [12,13].
Shortly thereafter, the patient developed a chest infection 
and died. Permission for autopsy was not granted, but the 
patient’s family has given written informed consent (as 
outlined in the PLoS consent form) for the publication of the 
details of his case.
DISCUSSION
Although PSP and AD may rarely occur together, in this 
case the clinical features and confirmatory investigations 
eventually led instead to a single diagnosis of FTDP-17 
with a tau gene mutation. AD and PSP are usually distinct 
conditions. Although both are neurodegenerative disorders 
that may cause dementia, typically the pattern of cognitive 
deficits differs: in AD there is prominent amnesia, with 
impaired encoding of new information, with or without 
agnosia, aphasia, and apraxia; whereas in PSP there is 
slowness of thought, altered personality with apathy, and 
forgetfulness with impaired retrieval of information [14].
Prior reports of the signs of PSP developing in AD have not 
been identified; eye movement abnormalities, nuchal rigidity, 
and early falls are not features of AD, although parkinsonism 
may occur, typically in the later stages. There have been 
occasional reports of AD pathology in PSP and of AD/PSP 
overlap cases [15–17]. PSP has previously been reported to 
“evolve” on occasion in patients initially diagnosed with the 
PNFA phenotype of FTLD [18,19], but this patient did not 
have a PNFA phenotype. 
Mutations in the gene encoding microtubule-associated 
protein tau (MAPT) typically present with a frontotemporal 
dementia phenotype with or without a parkinsonian 
syndrome—hence the clinical nomenclature of FTDP-17 [12]. 
Phenotypic heterogeneity has been reported in association 
with MAPT mutations: for example, an AD-like phenotype 
has been reported on occasion [20], including cases with 
the splice site 10 + 16 mutation [21,22]. This particular 
mutation has also been identified in a patient presenting 
with apparently sporadic young-onset PSP [23]. The current 
case suggests that tau gene analysis should be undertaken in 
individuals with a phenotype initially suggestive of AD who 
develop signs suggestive of PSP, as well as in patients with a 
diagnosis of “young-onset familial AD” who prove negative for 
mutations in genes deterministic for AD (amyloid precursor 
protein, presenilin 1 and 2) [22]. No specific treatments for 
frontotemporal dementia and progressive supranuclear palsy 
are available, but symptomatic drug and non-pharmacological 
treatments are sometimes tried. 
With the benefit of hindsight, the initial misdiagnosis 
in this patient might possibly have been avoided by more 
detailed initial neuropsychological assessment, and by use 
of other neuroimaging modalities, both structural and 
functional. Although temporal lobe atrophy can be seen in 
both AD and FTLD, the distribution of focal atrophy can 
be diagnostically helpful, and functional imaging may show 
different distributions of hypoperfusion (single-photon 
emission computerized tomography or SPECT scanning) 
and hypometabolism (positron emission tomography or PET 
scanning) [5].  
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